SA516370751B1 - تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي - Google Patents

تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي Download PDF

Info

Publication number
SA516370751B1
SA516370751B1 SA516370751A SA516370751A SA516370751B1 SA 516370751 B1 SA516370751 B1 SA 516370751B1 SA 516370751 A SA516370751 A SA 516370751A SA 516370751 A SA516370751 A SA 516370751A SA 516370751 B1 SA516370751 B1 SA 516370751B1
Authority
SA
Saudi Arabia
Prior art keywords
protein
fxa
clotting factor
light chain
factor
Prior art date
Application number
SA516370751A
Other languages
Arabic (ar)
English (en)
Inventor
جين شارب بينيلوب
سي. راوز جيسن
بي. ويستن ستيسي
ايه. جونسن كيث
بيث سويتزر ماري
أنتوني جانكوسكي مايكل
شاماشكين مايكل
كارول بياسينزا ويندي
Original Assignee
فايزر انك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by فايزر انك. filed Critical فايزر انك.
Publication of SA516370751B1 publication Critical patent/SA516370751B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
SA516370751A 2013-09-24 2016-03-17 تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي SA516370751B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24

Publications (1)

Publication Number Publication Date
SA516370751B1 true SA516370751B1 (ar) 2018-04-05

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
SA516370751A SA516370751B1 (ar) 2013-09-24 2016-03-17 تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي

Country Status (19)

Country Link
US (3) US9757434B2 (https=)
EP (1) EP3049434A1 (https=)
JP (1) JP6429885B2 (https=)
KR (1) KR101988705B1 (https=)
CN (2) CN112195169A (https=)
AR (1) AR097732A1 (https=)
AU (1) AU2014326257B2 (https=)
BR (1) BR112016005899A8 (https=)
CA (1) CA2924981C (https=)
HK (1) HK1218760A1 (https=)
IL (2) IL244258A0 (https=)
MX (1) MX373466B (https=)
MY (1) MY173548A (https=)
PE (1) PE20160877A1 (https=)
RU (1) RU2648144C2 (https=)
SA (1) SA516370751B1 (https=)
SG (1) SG11201601221XA (https=)
TW (1) TWI631134B (https=)
WO (1) WO2015044836A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
MX2011004907A (es) * 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
TW201217527A (en) * 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3063170A4 (en) 2013-11-01 2017-06-28 The Children's Hospital of Philadelphia Compositions and methods for increasing the half-life of factor xa
BR112016014617A2 (pt) 2014-01-24 2017-09-19 Pfizer Variante do fator xa (fxa) e usos da referida variante

Also Published As

Publication number Publication date
RU2016108608A (ru) 2017-10-26
JP6429885B2 (ja) 2018-11-28
WO2015044836A1 (en) 2015-04-02
KR20160044034A (ko) 2016-04-22
US20210106658A1 (en) 2021-04-15
BR112016005899A8 (pt) 2018-02-06
AU2014326257A1 (en) 2016-03-10
TWI631134B (zh) 2018-08-01
MY173548A (en) 2020-02-04
US20150182604A1 (en) 2015-07-02
IL279396A (en) 2021-01-31
MX373466B (es) 2020-05-25
TW201524996A (zh) 2015-07-01
HK1218760A1 (zh) 2017-03-10
PE20160877A1 (es) 2016-09-11
US10660946B2 (en) 2020-05-26
US9757434B2 (en) 2017-09-12
CN105579468A (zh) 2016-05-11
EP3049434A1 (en) 2016-08-03
US20170333535A1 (en) 2017-11-23
MX2016003871A (es) 2016-08-04
SG11201601221XA (en) 2016-04-28
CN112195169A (zh) 2021-01-08
BR112016005899A2 (pt) 2017-09-26
JP2016535071A (ja) 2016-11-10
RU2648144C2 (ru) 2018-03-22
AU2014326257B2 (en) 2017-08-10
CA2924981A1 (en) 2015-04-02
KR101988705B1 (ko) 2019-06-12
IL244258A0 (en) 2016-04-21
AR097732A1 (es) 2016-04-13
CA2924981C (en) 2020-03-31

Similar Documents

Publication Publication Date Title
Esmon et al. Structure, assembly, and secretion of octameric invertase.
Michelfelder et al. Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders
AU2021261911B2 (en) Polypeptides modulating SIGLEC dependent immune responses
EA012162B1 (ru) Способ рефолдинга рекомбинантных антител
NO321096B1 (no) Fremgangsmate for forbedring av in vivo-funksjonen av rekombinant faktor VIII SQ ved a skjerme utsatte mal pa polypeptidet
SA516370751B1 (ar) تركيبات تشمل مجموعات متغايرة من بروتينات xa لعامل تخثر آدمي تخليقي
ES2349112T3 (es) Método de purificación de factor vii.
CN111349142B (zh) 一种蛋白质的纯化方法
US20250257347A1 (en) Coagulation factor x activating enzyme and use thereof
CN103814137A (zh) 处理凝血因子的方法
Tsai et al. Effects of single N-glycosylation site knockout on folding and defibrinogenating activities of acutobin recombinants from HEK293T
Kittur et al. Two-step purification procedure for recombinant human asialoerythropoietin expressed in transgenic plants
HK40003560B (en) Polypeptides modulating siglec dependent immune responses
HK40003560A (en) Polypeptides modulating siglec dependent immune responses